This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, F.
Right arrow Articles by Kuwahara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, F.
Right arrow Articles by Kuwahara, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2000, p. 614-618, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis

Fumiaki Ikeda,1,* Yoshimi Wakai,1 Satoru Matsumoto,1 Katsuyuki Maki,1 Etsuko Watabe,1 Shuichi Tawara,1 Toshio Goto,1 Yuji Watanabe,2 Fumio Matsumoto,3 and Shogo Kuwahara4

Medicinal Biology Research Laboratories1 and Research Planning,2 Fujisawa Pharmaceutical Co., Ltd., Kashima, Yodogawa-ku, Osaka 532-8514, Kanagawa Prefectural Nursing and Hygienic School Hospital, 1-6, Shiomidai, Isogo-ku, Yokohama 235-0022,3 and Toho University School of Medicine, Ohmori Nishi, Ohta-ku, Tokyo 143-8540,4 Japan

Received 3 May 1999/Returned for modification 26 July 1999/Accepted 10 December 1999

The efficacy of intravenous injection of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of disseminated candidiasis and aspergillosis and was compared with those of fluconazole (FLCZ) and amphotericin B (AMPH-B). In the candidiasis model, FK463 significantly prolonged the survival of intravenously infected mice at doses of 0.125 mg/kg of body weight or higher. In disseminated candidiasis caused by Candida species, including FLCZ-resistant Candida albicans, FK463 exhibited an efficacy 1.4 to 18 times inferior to that of AMPH-B, with 50% effective doses (ED50s) ranging from 0.21 to 1.00 mg/kg and 0.06 to 0.26 mg/kg, respectively, and was much more active than FLCZ. The protective effect of FK463 was not obviously influenced by the fungal inoculum size, the starting time of the treatment, or the immunosuppressed status of the host. The reduction in efficacy was less than that observed with FLCZ or AMPH-B. The efficacy of FK463 was also evaluated in the disseminated candidiasis target organ assay and was compared with those of FLCZ and AMPH-B. Efficacies were evaluated on the basis of a comparison between the mean log10 CFU in kidneys in the groups treated with antifungal agents and that in control group. A single dose of FK463 at 0.5 mg/kg or higher significantly reduced the viable counts in kidneys compared with the numbers of yeast cells before treatment, and its efficacy was comparable to that of AMPH-B, while FLCZ at 4 mg/kg showed only a suppressive effect on the growth of C. albicans in the kidneys. In the disseminated aspergillosis model, FK463 given at doses of 0.5 mg/kg or higher significantly prolonged the survival of mice infected intravenously with Aspergillus fumigatus conidia. The efficacy of FK463 was about 2 times inferior to that of AMPH-B, with ED50s ranging from 0.25 to 0.50 mg/kg and 0.11 to 0.29 mg/kg, respectively. These results indicate that FK463 may be a potent parenterally administered therapeutic agent for disseminated candidiasis and aspergillosis.

* Corresponding author. Mailing address: Department of Infectious Diseases, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome, Kashima, Yodogawa-Ku, Osaka 532-8514, Japan. Phone: 81-6-6390-1158. Fax: 81-6-6304-5367. E-mail: fumiaki_ikeda{at}po.fujisawa.co.jp.

Antimicrobial Agents and Chemotherapy, March 2000, p. 614-618, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., Narita, H. (2008). In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine. Antimicrob. Agents Chemother. 52: 1318-1324 [Abstract] [Full Text]  
  • Keirns, J., Sawamoto, T., Holum, M., Buell, D., Wisemandle, W., Alak, A. (2007). Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults. Antimicrob. Agents Chemother. 51: 787-790 [Abstract] [Full Text]  
  • Seibel, N. L., Schwartz, C., Arrieta, A., Flynn, P., Shad, A., Albano, E., Keirns, J., Lau, W. M., Facklam, D. P., Buell, D. N., Walsh, T. J. (2005). Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients. Antimicrob. Agents Chemother. 49: 3317-3324 [Abstract] [Full Text]  
  • Sato, I., Yamamoto, N., Yamazaki, H., Hashimoto, S., Hino, M., Sakai, F., Fujie, A. (2005). Prevention of the Cryptic Epitope SLAYGLR within Osteopontin Does Not Influence Susceptibility to Candida albicans Infection. Antimicrob. Agents Chemother. 49: 3053-3055 [Abstract] [Full Text]  
  • Hiemenz, J., Cagnoni, P., Simpson, D., Devine, S., Chao, N., Keirns, J., Lau, W., Facklam, D., Buell, D. (2005). Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant. Antimicrob. Agents Chemother. 49: 1331-1336 [Abstract] [Full Text]  
  • Ninomiya, M., Mikamo, H., Tanaka, K., Watanabe, K., Tamaya, T. (2005). Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice. J Antimicrob Chemother 55: 587-590 [Abstract] [Full Text]  
  • Serena, C., Pastor, F. J., Gilgado, F., Mayayo, E., Guarro, J. (2005). Efficacy of Micafungin in Combination with Other Drugs in a Murine Model of Disseminated Trichosporonosis. Antimicrob. Agents Chemother. 49: 497-502 [Abstract] [Full Text]  
  • MacCallum, D. M., Odds, F. C. (2004). Need for Early Antifungal Treatment Confirmed in Experimental Disseminated Candida albicans Infection. Antimicrob. Agents Chemother. 48: 4911-4914 [Abstract] [Full Text]  
  • Carver, P. L (2004). Micafungin. The Annals of Pharmacotherapy 38: 1707-1721 [Abstract] [Full Text]  
  • Hamamoto, H., Kurokawa, K., Kaito, C., Kamura, K., Manitra Razanajatovo, I., Kusuhara, H., Santa, T., Sekimizu, K. (2004). Quantitative Evaluation of the Therapeutic Effects of Antibiotics Using Silkworms Infected with Human Pathogenic Microorganisms. Antimicrob. Agents Chemother. 48: 774-779 [Abstract] [Full Text]  
  • Arikan, S., Yurdakul, P., Hascelik, G. (2003). Comparison of Two Methods and Three End Points in Determination of In Vitro Activity of Micafungin against Aspergillus spp.. Antimicrob. Agents Chemother. 47: 2640-2643 [Abstract] [Full Text]  
  • Watabe, E., Nakai, T., Matsumoto, S., Ikeda, F., Hatano, K. (2003). Killing Activity of Micafungin against Aspergillus fumigatus Hyphae Assessed by Specific Fluorescent Staining for Cell Viability. Antimicrob. Agents Chemother. 47: 1995-1998 [Abstract] [Full Text]  
  • Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 1187-1192 [Abstract] [Full Text]  
  • Nakai, T., Uno, J., Ikeda, F., Tawara, S., Nishimura, K., Miyaji, M. (2003). In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms. Antimicrob. Agents Chemother. 47: 1376-1381 [Abstract] [Full Text]  
  • Luque, J. C., Clemons, K. V., Stevens, D. A. (2003). Efficacy of Micafungin Alone or in Combination against Systemic Murine Aspergillosis. Antimicrob. Agents Chemother. 47: 1452-1455 [Abstract] [Full Text]  
  • Warn, P. A., Morrissey, G., Morrissey, J., Denning, D. W. (2003). Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 51: 913-919 [Abstract] [Full Text]  
  • Petraitis, V., Petraitiene, R., Groll, A. H., Roussillon, K., Hemmings, M., Lyman, C. A., Sein, T., Bacher, J., Bekersky, I., Walsh, T. J. (2002). Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 46: 1857-1869 [Abstract] [Full Text]  
  • Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., Walsh, T. J. (2001). Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. 45: 3310-3321 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Ibrahim, K. H., Piscitelli, S. C., Bekersky, I., Walsh, T. J. (2001). Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits. Antimicrob. Agents Chemother. 45: 3322-3327 [Abstract] [Full Text]  
  • Muller, F.-M. C., Kurzai, O., Hacker, J., Frosch, M., Muhlschlegel, F. (2001). Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 48: 713-715 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»